<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218018/" ref="ordinalpos=3596&amp;ncbi_uid=3666588&amp;link_uid=PMC3218018" image-link="/pmc/articles/PMC3218018/figure/pone-0027710-g003/" class="imagepopup">Figure 3. NDRG2 affects TGF-β1/Smad <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> and the ratio of MMP2 to TIMP2 in LX-2 cells..  From: NDRG2 Ameliorates Hepatic Fibrosis by Inhibiting the TGF-?1/Smad <span class="highlight" style="background-color:">Pathway</span> and Altering the MMP2/TIMP2 Ratio in Rats. </a></div><br /><div class="p4l_captionBody">(A) Real-time PCR was used to detect the expression of Smad2, Smad3 and Smad7 in LX-2 cells with TGF-β1 and/or adenovirus treatment. (B) Western blotting was used to detect the expression of Smad2, phospho-Smad2, Smad3, phospho-Smad3 and Smad7 in LX-2 cells with TGF-β1 and/or adenovirus treatment. (C) Real-time PCR was used to detect the expression of MMP2 and TIMP2 in LX-2 cells following TGF-β1 and/or adenovirus treatment. β-actin was used as a loading control. All experiments were performed independently in triplicate. *P&lt;0.05 compared with the TGF-β1 or TGF-β1+AdLacZ group.</div></div>